We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add RNTX Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
RNTX resumed the RENEW study after the FDA lifted its clinical hold on LTI-03 in November 2025.
RNTX started phase II dosing in March 2026 and expects enrollment to continue through mid-2027.
LTI-03 gained FDA Fast Track and EMA Orphan Drug designations, supporting its IPF development.
Rein Therapeutics (RNTX - Free Report) continues to advance its lead candidate LTI-03, a first-in-class, inhaled peptide therapy being developed for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. LTI-03 is designed to mimic the biological activity of Caveolin-1, a protein involved in maintaining tissue integrity and supporting tissue repair. By modulating multiple pathways associated with fibrosis while protecting lung cells, LTI-03 is intended to address the underlying biology of fibrotic disease rather than targeting a single pathway.
FDA Resolution of Clinical Hold Clears Path for RENEW
The development program experienced a huge regulatory setback in 2025 when the FDA placed a clinical hold on the phase II RENEW study of LTI-03, prompting Rein Therapeutics to pause enrollment and dosing in the United States. The regulatory authority requested that the company conduct an additional study and provide sufficient nonclinical safety information in support of the RENEW study.
The clinical hold was lifted following a review of the company’s submission, which addressed all of the agency’s concerns, clearing the way for the company to resume clinical development of LTI-03 and advance the RENEW study.
Year to date, shares of Rein Therapeutics have lost 32.7% against the industry’s 9.7% growth.
Image Source: Zacks Investment Research
RNTX’s Phase II RENEW Study Provides a Near-Term Catalyst
A key catalyst for the stock is the continued advancement of the phase II RENEW study. The randomized, double-blind, placebo-controlled study is being conducted across five countries, including the United States, the United Kingdom, Germany, Australia and Poland.
Rein Therapeutics initiated patient dosing in March 2026, marking a significant transition of LTI-03 into its phase II clinical development stage. The company expects to continue enrolling patients through mid-2027 and plans to expand the study to as many as 50 clinical sites as enrollment progresses.
As of August 2026, Rein Therapeutics surpassed 25% of planned enrollment, with management indicating that enrollment was progressing ahead of schedule. The company remains on track to report interim study data in the fourth quarter of 2026.
The upcoming interim readout could be a meaningful catalyst for RNTX, as positive evidence of biological activity, lung-function preservation or other clinically relevant effects could strengthen confidence in LTI-03's development potential.
Per management, LTI-03 has the potential to be a differentiated multi-pathway treatment for patients with IPF and deliver anti-fibrotic and potentially regenerative effects alongside a favorable safety and tolerability profile.
Last month, the FDA granted Fast Track Designation to the candidate. Earlier in 2026, the candidate received Orphan Drug designation from theEuropean Medicines Agency for the treatment of IPF.
Beyond its lead IPF program, Rein Therapeutics has additional pipeline assets that could provide longer-term value optionality. The company previously advanced LTI-01 for loculated pleural effusion, an indication for which there are no approved drug treatments and has also described preclinical programs targeting cystic fibrosis and systemic fibrosis.
However, these programs are currently paused as Rein Therapeutics focuses its resources on advancing LTI-03. Consequently, the assets should be viewed primarily as longer-term pipeline optionality rather than immediate stock catalysts.
RNTX's Zacks Rank & Estimates
Rein Therapeutics currently carries a Zacks Rank #2 (Buy). Over the past 60 days, estimates for RNTX’s 2026 loss per share have narrowed from 53 cents to 47 cents and estimates for its 2027 loss per share have remained unchanged at 50 cents.
Improving estimates, favorable regulatory developments, and encouraging pipeline progress position this stock as a compelling yet high-risk, high-reward investment opportunity. Positive RENEW interim data in the fourth quarter of 2026 could drive meaningful gains, while disappointing results could lead to a sharp decline. Thus, the stock may be attractive for risk-tolerant investors.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 68% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 9.6% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 30 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.1% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add RNTX Stock to Your Portfolio Now
Key Takeaways
Rein Therapeutics (RNTX - Free Report) continues to advance its lead candidate LTI-03, a first-in-class, inhaled peptide therapy being developed for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. LTI-03 is designed to mimic the biological activity of Caveolin-1, a protein involved in maintaining tissue integrity and supporting tissue repair. By modulating multiple pathways associated with fibrosis while protecting lung cells, LTI-03 is intended to address the underlying biology of fibrotic disease rather than targeting a single pathway.
FDA Resolution of Clinical Hold Clears Path for RENEW
The development program experienced a huge regulatory setback in 2025 when the FDA placed a clinical hold on the phase II RENEW study of LTI-03, prompting Rein Therapeutics to pause enrollment and dosing in the United States. The regulatory authority requested that the company conduct an additional study and provide sufficient nonclinical safety information in support of the RENEW study.
The clinical hold was lifted following a review of the company’s submission, which addressed all of the agency’s concerns, clearing the way for the company to resume clinical development of LTI-03 and advance the RENEW study.
Year to date, shares of Rein Therapeutics have lost 32.7% against the industry’s 9.7% growth.
Image Source: Zacks Investment Research
RNTX’s Phase II RENEW Study Provides a Near-Term Catalyst
A key catalyst for the stock is the continued advancement of the phase II RENEW study. The randomized, double-blind, placebo-controlled study is being conducted across five countries, including the United States, the United Kingdom, Germany, Australia and Poland.
Rein Therapeutics initiated patient dosing in March 2026, marking a significant transition of LTI-03 into its phase II clinical development stage. The company expects to continue enrolling patients through mid-2027 and plans to expand the study to as many as 50 clinical sites as enrollment progresses.
As of August 2026, Rein Therapeutics surpassed 25% of planned enrollment, with management indicating that enrollment was progressing ahead of schedule. The company remains on track to report interim study data in the fourth quarter of 2026.
The upcoming interim readout could be a meaningful catalyst for RNTX, as positive evidence of biological activity, lung-function preservation or other clinically relevant effects could strengthen confidence in LTI-03's development potential.
Per management, LTI-03 has the potential to be a differentiated multi-pathway treatment for patients with IPF and deliver anti-fibrotic and potentially regenerative effects alongside a favorable safety and tolerability profile.
Last month, the FDA granted Fast Track Designation to the candidate. Earlier in 2026, the candidate received Orphan Drug designation from theEuropean Medicines Agency for the treatment of IPF.
Rein Therapeutics Inc. Price and Consensus
Rein Therapeutics Inc. price-consensus-chart | Rein Therapeutics Inc. Quote
Pipeline Optionality Beyond LTI-03
Beyond its lead IPF program, Rein Therapeutics has additional pipeline assets that could provide longer-term value optionality. The company previously advanced LTI-01 for loculated pleural effusion, an indication for which there are no approved drug treatments and has also described preclinical programs targeting cystic fibrosis and systemic fibrosis.
However, these programs are currently paused as Rein Therapeutics focuses its resources on advancing LTI-03. Consequently, the assets should be viewed primarily as longer-term pipeline optionality rather than immediate stock catalysts.
RNTX's Zacks Rank & Estimates
Rein Therapeutics currently carries a Zacks Rank #2 (Buy). Over the past 60 days, estimates for RNTX’s 2026 loss per share have narrowed from 53 cents to 47 cents and estimates for its 2027 loss per share have remained unchanged at 50 cents.
Improving estimates, favorable regulatory developments, and encouraging pipeline progress position this stock as a compelling yet high-risk, high-reward investment opportunity. Positive RENEW interim data in the fourth quarter of 2026 could drive meaningful gains, while disappointing results could lead to a sharp decline. Thus, the stock may be attractive for risk-tolerant investors.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 68% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 9.6% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 30 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.1% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.